Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Cancer Discov. 2020 Oct 7;11(2):500–519. doi: 10.1158/2159-8290.CD-20-0318

Figure 6.

Figure 6.

Leukemic infiltration induces liver damage and creates a chemo-protective microenvironment.

A-D, AST (A), ALT (B), XO (C) and CDA (D) activities in sera from normal and leukemic mice (n=4).

E, Ara-C was preincubated with serum from normal or leukemic mice or H2O for 24 h at 37 ⁰C. One group of bulk leukemia cells were treated with preincubated Ara-C, the other group were treated with Ara-C without preincubation and supplemented with equal amount of either normal or leukemic serum as the first group. Viability of leukemia cells were examined 24 h after treatment. Error bars denote mean ± SD from triplicates.

F, Relative serum xanthine and hypoxanthine levels in normal and leukemic mice (n=4).

G, Ara-C was incubated with normal or leukemic serum for 24h at 37 ⁰C (final concentration of cytarabine: 100nM). Ara-C and Ara-U concentration were determined by mass spectrometry after incubation(n=6).

H-I, Plasma activity of AST (H) and CDA (I) in portal vein and hepatic vein from normal and leukemic mice (n=5).

J, Leukemic mice were treated with short-term chemotherapy (consisting of 2-day treatment of Ara-C (50 mg/kg, i.p.) and doxorubicin (1.5 mg/kg, i.p.). BM and liver leukemic burden, leukemic cell number (per whole liver or per femur + tibia) and leukemia cell number fold changed were determined (n=5).

Error bars denote mean ± SD. *p<0.05, **p<0.005, ***p<0.0005, ****p<0.00005.